Real-world palbociclib dose modifications and clinical outcomes in patients with HR+/HER2− metastatic breast cancer: A Flatiron Health database analysis

Authors

Institutions

Publication Details

Journal
The Breast
Published
2025-03-17
DOI
https://doi.org/10.1016/j.breast.2025.104448
Citations
3
Primary Topic
Advanced Breast Cancer Therapies
Type
article
Field-Weighted Citation Impact
4.56

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Real-world palbociclib dose modifications and clinical outcomes in patients with HR+/HER2− metastatic breast cancer: A Flatiron Health database analysis

Benjamin Li, Lynn McRoy, Adam Brufsky, Rachel M. Layman et al.
3 citations
The Breast
Advanced Breast Cancer Therapies
4.56
article

Real-world palbociclib dose modifications and clinical outcomes in patients with HR+/HER2− metastatic breast cancer: A Flatiron Health database analysis

Benjamin Li, Lynn McRoy, Adam Brufsky, Rachel M. Layman, Xianchen Liu
article en
3 citations

Abstract

No abstract available for this paper.
The BreastVol. 81
The University of Texas MD Anderson Cancer Center (US), Pfizer (United States) (US), University of Pittsburgh Medical Center (US)
Pfizer
Good health and well-being
Openalex Percentile: Top 6%
Advanced Breast Cancer Therapies
4.56
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.